Linkedin Facebook Twitter
Sign up

/DISREGARD RELEASE: Daewoong Pharmaceutical Co., Ltd./

Journalists and other readers should disregard the news release, Daewoong Pharmaceutical Announces Successful ‘Extra Strength’ Results of US Phase 2 Clinical Trial for High-dose Administration of NABOTA, issued earlier today. The release was transmitted prematurely by PR Newswire.

Subscribe on LinkedIn
Clinical Trials & Medical Discoveries

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Topics

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.